PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29308748-6 2018 RESULTS: Both groups demonstrated a significant increase in their CD4+ T cell count which was greater in Zidovudine/Lamivudine and Efavirenz treated group. efavirenz 131-140 CD4 molecule Homo sapiens 66-69 33116922-12 2020 Health-care providers should give attention to patients on efavirenz therapy to monitor for CNS adverse events, especially for patients who have low CD4 count, advanced disease, comorbidities, low income and are older in age. efavirenz 59-68 CD4 molecule Homo sapiens 149-152 32702281-5 2020 Compared to regimens containing lopinavir, we found that atazanavir-, efavirenz-, and raltegravir-based regimens were superior in achieving both outcomes after adjustment for age, social vulnerability index, time under ART, baseline CD4+ cell count, and baseline HIV VL. efavirenz 70-79 CD4 molecule Homo sapiens 233-236 29534103-8 2018 RESULTS: In the CD4+ T-cell population, HIVpt affected 13/30 of patients on EFV versus 10/21 on ATV. efavirenz 76-79 CD4 molecule Homo sapiens 16-19 29534103-9 2018 In the CD4+CD45RO+ T-cell population, HIVpt was present in 14/30 of patients on EFV versus 15/21 on ATV. efavirenz 80-83 CD4 molecule Homo sapiens 7-10 31409277-10 2019 Median body mass index and CD4 count at efavirenz commencement was 21 (IQR: 19-23) and 260 cells/mm3 (IQR: 126-412) respectively. efavirenz 40-49 CD4 molecule Homo sapiens 27-30 29875890-8 2018 From EFV+AZT+3TC group, the mean CD4 cell count difference from baseline was 205(95% CI 155.404-235.623, p< 0.001). efavirenz 5-8 CD4 molecule Homo sapiens 33-36 29308748-8 2018 CONCLUSION: A rapid CD4+ Tcell increase occurred shortly after beginning ART consisting either Vonavir or combination of Zidovudine, Lamivudine and Efavirenz. efavirenz 148-157 CD4 molecule Homo sapiens 20-23 29308748-9 2018 Late increases in CD4+ T cell counts were more pronounced in therapy using Zidovudine/ Lamivudine and Efavirenz. efavirenz 102-111 CD4 molecule Homo sapiens 18-21 27646953-5 2016 CASES PRESENTATION: A first case was a 33 years-old female newly diagnosed HIV patient with CD4 count of 4 cells/muL (0 %), normal complete blood count, liver and renal function tests was started on co-formulated tenofovir/emtricitabine/efavirenz and prophylactic cotrimoxazole. efavirenz 237-246 CD4 molecule Homo sapiens 92-95 28143541-14 2017 The predicted CD4+ count for TDF/3TC/EFV was (B = +347.65 cells/mm3, P < 0.001) whereas that of AZT/3TC/EFV was (B = +281.54 cells/mm3, P < 0.001). efavirenz 37-40 CD4 molecule Homo sapiens 14-17 26945366-9 2016 Treatment with efavirenz rather than nevirapine was associated with increased risk of developing diabetes (hazard ratio 1.27 (95% confidence interval (CI): 1.10-1.46)) in a multivariate analysis adjusting for age, sex, body mass index, baseline CD4 count, viral load, NRTI backbone, and exposure to other diabetogenic medicines. efavirenz 15-24 CD4 molecule Homo sapiens 245-248 26906233-4 2016 He was receiving treatment with efavirenz, emtricitabine and tenofovir, his CD4 count was 580/mm3 and HIV viral load was undetectable. efavirenz 32-41 CD4 molecule Homo sapiens 76-79 25777186-9 2015 The mean changes from baseline in CD4 count were similar in both rilpivirine and efavirenz (RR = 1.05, 95% CI: 0.85-1.24). efavirenz 81-90 CD4 molecule Homo sapiens 34-37 30222398-8 2015 In multivariate analysis, efavirenz-based regimens showed more likelihood of immunologic recovery, whether defined as a CD4 cell count of >200 cells/mm3 (hazard ratio [HR] = 1.31 [95% CI, 1.05-1.59]), >350 cells/mm3 (HR = 1.26 [95% CI, 1.08-1.47]), or >500 cells/mm3 (HR = 1.95 [95% CI, 1.57-2.41]). efavirenz 26-35 CD4 molecule Homo sapiens 120-123 23372824-8 2013 Children receiving EFV experienced increases in both CD4(+) T-cell percentage and weight-for-age z-score during follow-up, such that levels were comparable to children receiving NVP after two years of ART. efavirenz 19-22 CD4 molecule Homo sapiens 53-56 25433665-9 2014 The mean changes from baseline in CD4 count were similar in both rilpivirine and efavirenz (RR, 1.05; 95% CI, 0.85-1.24). efavirenz 81-90 CD4 molecule Homo sapiens 34-37 22309114-8 2012 In addition, adults initiating EFV-based cART at higher baseline CD4(+) cell count values had more favorable outcomes compared to those initiating NVP-based cART. efavirenz 31-34 CD4 molecule Homo sapiens 65-68 20404738-4 2010 Mean change in baseline CD4 count was 240 and 225 cells per cubic millimeter in the raltegravir and efavirenz groups, respectively [Delta (95% confidence interval) = 15 (-13 to 42)]. efavirenz 100-109 CD4 molecule Homo sapiens 24-27 20090545-0 2010 Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico. efavirenz 45-54 CD4 molecule Homo sapiens 116-119 18097230-6 2008 Median CD4 cell counts increased above respective baselines by 292 cells/mul (efavirenz, zidovudine, lamivudine and indinavir, zidovudine, lamivudine) and 300 cells/mul (efavirenz plus indinavir). efavirenz 170-179 CD4 molecule Homo sapiens 7-10 18419537-0 2008 Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. efavirenz 0-9 CD4 molecule Homo sapiens 103-106 18097230-6 2008 Median CD4 cell counts increased above respective baselines by 292 cells/mul (efavirenz, zidovudine, lamivudine and indinavir, zidovudine, lamivudine) and 300 cells/mul (efavirenz plus indinavir). efavirenz 78-87 CD4 molecule Homo sapiens 7-10 17667341-7 2007 Women had lower CD4 counts when starting EFV (median [interquartile range [IQR] = 126 [36, 220] cells/mm for women vs. 190 [109, 268] cells/mm for men; P = 0.0003). efavirenz 41-44 CD4 molecule Homo sapiens 16-19 17713424-9 2007 Some cohort studies and randomized clinical trials support the use of efavirenz-based antiretroviral therapy for the treatment of advanced HIV-1-infected patients; however, recent randomized controlled data suggest, in a moderately advanced HIV population, a better CD4 cell recovery for lopinavir-ritonavir than for efavirenz-treated patients, but a greater virological suppression in the efavirenz arm. efavirenz 70-79 CD4 molecule Homo sapiens 266-269 17653450-8 2007 The mean CD4 cell count increase after a 12-month period was also greater in the efavirenz group (195 x 10(6) cells/L) than in the nelfinavir group (119 x 10(6) cells/L; P = 0.002). efavirenz 81-90 CD4 molecule Homo sapiens 9-12 17057609-7 2006 The TDF + FTC + EFV group demonstrated a significantly greater increase in CD4 count (270 vs. 237 cells/mm; P = 0.036). efavirenz 16-19 CD4 molecule Homo sapiens 75-78 17334006-8 2006 In the random effects model, there was an increase of 40.97 (p < 0.05) units of CD4 cell counts with an unit increase in time in the NVP arm as against a 44.75 (p < 0.05) units of increase in CD4 cell counts in the EFV group with a unit increase in time, which is significant for both groups. efavirenz 221-224 CD4 molecule Homo sapiens 83-86 9878993-7 1998 Once-daily efavirenz in combination with zidovudine plus lamivudine or indinavir or nelfinavir increased CD4+ cell counts and reduced HIV RNA plasma levels to below quantifiable levels (< 400 copies/ml) in HIV-infected patients. efavirenz 11-20 CD4 molecule Homo sapiens 105-108 16452064-3 2005 RESULTS: The two study groups were comparable, except for the lower baseline CD4+ count found in the EFV group. efavirenz 101-104 CD4 molecule Homo sapiens 77-80 17100373-14 2006 CONCLUSION: Initiation of EFV-based HAART regimen in HIV-infected patients at CD4 < 100 and > or = 100 cells/ mm3 gains similar immunological and virological response. efavirenz 26-29 CD4 molecule Homo sapiens 78-81 34280356-8 2021 Efavirenz use can negatively influence vitamin D levels and supplementation is necessary as a likely adjunct to improving CD4+ T cells, resulting in greater effectiveness of the treatment. efavirenz 0-9 CD4 molecule Homo sapiens 122-125